Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lucid Diagnostics (LUCD) Payables (2020 - 2026)

Lucid Diagnostics filings provide 6 years of Payables readings, the most recent being $25.0 million for Q4 2025.

  • On a quarterly basis, Payables rose 25.85% to $25.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $25.0 million, a 25.85% increase, with the full-year FY2025 number at $25.0 million, up 25.85% from a year prior.
  • Payables hit $25.0 million in Q4 2025 for Lucid Diagnostics, up from $24.6 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $34.9 million in Q1 2025 to a low of $1.1 million in Q4 2022.
  • Median Payables over the past 5 years was $14.0 million (2023), compared with a mean of $13.4 million.
  • Biggest five-year swings in Payables: plummeted 60.29% in 2022 and later surged 1272.7% in 2023.
  • Lucid Diagnostics' Payables stood at $1.1 million in 2021, then fell by 5.12% to $1.1 million in 2022, then soared by 1223.48% to $14.0 million in 2023, then soared by 41.96% to $19.8 million in 2024, then grew by 25.85% to $25.0 million in 2025.
  • The last three reported values for Payables were $25.0 million (Q4 2025), $24.6 million (Q3 2025), and $26.1 million (Q2 2025) per Business Quant data.